The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acquired | Acquired

Total Raised


About Torax Medical

Torax Medical is a medical device company that develops and markets products designed to treat chronic diseases related to defective sphincter muscles. The company's technology platform, Magnetic Sphincter Augmentation (MSA), employs a small implant comprised of interlinked titanium beads with magnetic cores. The magnetic attraction between the beads augments the existing sphincter's barrier function to prevent reflux or incontinence. The devices are implanted with standard minimally invasive laparoscopic or surgical procedures.

Torax Medical Headquarter Location

4188 Lexington Avenue North

Shoreview, Minnesota, 55126,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Torax Medical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Torax Medical is included in 2 Expert Collections, including Medical Devices.


Medical Devices

11,296 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,900 items

Torax Medical Patents

Torax Medical has filed 19 patents.

The 3 most popular patent topics include:

  • Digestive system
  • Esophagus disorders
  • Implants (medicine)
patents chart

Application Date

Grant Date


Related Topics




Mammal male reproductive system, Urinary system, Gynaecology, Penis, Women's health


Application Date


Grant Date



Related Topics

Mammal male reproductive system, Urinary system, Gynaecology, Penis, Women's health



Latest Torax Medical News

Entering the ‘age of enlightenment’ with a new generation of celiac disease leaders

Apr 19, 2022

Source: Healio interview Disclosures: Murray reports financial relationships with Allakos, Bionix, Boehringer Ingelheim, Celimmune, Chugai Pharmaceuticals, Cour Pharmaceuticals, Dr. Schär USA, Immunogenix, Johnson & Johnson, Kanyos Bio, Lilly, NIH, Nexpep/ImmusanT, Oberkotter, Precigen, Takeda Pharmaceuticals, Torax Medical and UCB Biopharma. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact . Back to Healio I’ve been engaged in celiac disease for more than 30 years, and for a long time it was what I call an orphaned disease, with less than a handful of expatriate academics exhibiting any interest in it. The irony is that in the ’60s there was great interest in celiac disease in academic gastroenterology, with GI giants publishing on celiac before it went out into the wilderness. A renaissance of interest was born in the ’90s and grew into what I call the “age of enlightenment,” where celiac disease is not only considered a major disease within GI but also an excellent example of an autoimmune disease. It is garnering a lot more attention as a model disease in which we can manipulate the immune system. Source: Adobe Stock. The other thing that’s changed tremendously is we have a new generation of leaders — like the many interviewed in this story — who are focusing on this disease. This piece really illustrates that celiac disease should be the bread and butter of GI practice. Every gastroenterologist must have a working knowledge of who to test, how to test and the intricacies of properly initiating and coordinating therapy. GIs need to be able to incorporate diagnosis and management guidelines into practice. Ideally, they will also be involved in following up with patients, even if they do not live near one of these centers of excellence. Joseph A. Murray Also apparent, especially because of the engagement of patient advocacy organizations, is that all is not well in the world of quality of life. Patients carry a terrific burden maintaining a gluten-free diet. There is a need for additional treatments: Our patients want them and should have them, presuming they have been shown to be safe and effective. As Alberto Rubio Tapia, MD, pointed out, we know a lot about the mechanisms of celiac disease. While there’s still a lot to discover, what we currently know has become the basis for developmental efforts for treatments beyond the gluten-free diet. The “age of enlightenment” also has brought to light the need for multidisciplinary involvement. It’s not just the gastroenterologist alone — patients need an expert dietitian. No patient should be started on or given a diagnosis that requires lifetime management without access to an expert nutritionist to help them live gluten-free. That’s just a basic expectation. There are so many people with celiac that this expertise should not only be widely available but also covered by insurance. Challenges within this disease still exist and are broad. Lisa M. Fahey, MD, was correct in her sentiment: There needs to be more support and funding for research, because this is a common disease, and it has a major impact on patients across the entire age spectrum. A major gap in knowledge also persists in the screening, diagnosis and management of this disease — namely, the key question of who to test. Nuanced differences exist between pediatric experts who test patients at high-risk and adult experts who test once patients have a hint of symptoms. We need more data to know whether we should be testing adults who are at risk but asymptomatic. By default, we are not testing for the disease because of lack of sufficient evidence, rather than erring on the side of caution and testing. Some people live with this disease for so long that they’ve accepted their life or their symptoms as normal. They don’t recognize that it’s not normal. Even after a celiac diagnosis, they continue to have symptoms and accept it, downplaying it partly as a method of self-preservation. By doing this, they’re making it harder to justify coming up with alternative treatments. I have seen this in all the clinical trials I performed. People have been suffering in silence for far too long. I could also make the rather provocative comment that celiac disease is the most common inflammatory bowel disease — it just hasn’t been accepted into that community of IBD doctors, even though it is chronic inflammation of the bowel. I suspect, or rather predict, that once there are drugs available beyond the gluten-free diet, we may see a lot more interest from those who have focused solely on IBD. Overall, with this new generation of researchers and clinicians, I see a lot of hope, energy and terrific enthusiasm for furthering our knowledge of celiac disease and giving our patients the best possible treatment. For more information: Joseph A. Murray, MD, is a professor of medicine in the department of gastroenterology and hepatology at Mayo Clinic. Read more about

  • When was Torax Medical founded?

    Torax Medical was founded in 2002.

  • Where is Torax Medical's headquarters?

    Torax Medical's headquarters is located at 4188 Lexington Avenue North, Shoreview.

  • What is Torax Medical's latest funding round?

    Torax Medical's latest funding round is Acquired.

  • How much did Torax Medical raise?

    Torax Medical raised a total of $104.2M.

  • Who are the investors of Torax Medical?

    Investors of Torax Medical include Ethicon, Sanderling Ventures, Mayo Clinic Ventures, Thomas McNerney & Partners, Accuitive Medical Ventures and 6 more.

  • Who are Torax Medical's competitors?

    Competitors of Torax Medical include EndoGastric Solutions, Apnex Medical, Lutonix, BARRx Medical, Evalve and 10 more.

You May Also Like

Endologix Logo

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

Chestnut Medical Technologies

Chestnut Medical Technologies, Inc. was founded to pioneer new minimally invasive therapies for Interventional Neuroradiology. Chestnut aims to develop technologies that are easier to use while improving outcomes and reducing complications in the treatment of neurovascular disease.

OmniSonics Medical Technologies

OmniSonics was a medical device company focused on developing breakthrough products for the treatment of vascular occlusive disease.


Otologics is a medical device company developing implantable hearing systems and accessories designed to enhance communication and improve the quality of life for individuals with hearing loss.


Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients. Satiety's first product, the TOGA System, enables physicians to perform a procedure similar to traditional restrictive obesity surgeries, but without surgical incisions. In this procedure, the TOGA System devices are inserted transorally (through the mouth) and are used to reduce the capacity of the stomach to give patients a feeling of fullness after a small meal. The procedure is intended to be safer and easier for patients to tolerate than conventional obesity surgery. Safety and effectiveness of the TOGA System are currently being evaluated in a multi-center U.S. Study and the system is not available for sale in the United States.


Otokinetics has been formed to create and promulgate an entirely new product category in hearing aid devices.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.